Overview

Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.
Phase:
Phase 2
Details
Lead Sponsor:
Ineos Healthcare Limited
Treatments:
Sevelamer